ABSTRACT
Objective@#Infertility can result from a diminished ovarian reserve, but a potential remedy exists in the form of platelet-rich plasma (PRP) administration. This treatment involves both biological factors and tissue trauma mechanisms, which stimulate folliculogenesis, making it a promising and effective strategy. We assessed the impact of direct PRP injections into the ovaries on the fertility outcomes of women classified as poor responders. @*Methods@#A quasi-experimental study was conducted from April 2021 to December 2022, focusing on patients classified as POSEIDON grade 3 or 4. PRP injections were administered into both ovaries. After 3 months, data were collected on anti-Müllerian hormone (AMH) level, follicle-stimulating hormone (FSH) level, and the numbers of oocytes, mature oocytes, and good-quality embryos following ovarian stimulation. We then compared the data from before and after PRP injection. @*Results@#This study included 50 women, with a mean of 39 years (interquartile range [IQR], 35 to 43) and 4 years (IQR, 2 to 6) for age and infertility duration, respectively. FSH levels decreased after treatment, while AMH levels and the numbers of oocytes, metaphase II oocytes, and high-quality embryos increased. However, only the increase in high-quality embryos was significant. The pregnancy and spontaneous pregnancy rates were 20% and 14%, respectively. Notably, women with secondary infertility exhibited a significantly higher pregnancy rate than those with primary infertility. @*Conclusion@#Ample evidence suggests that PRP can enhance ovarian function. However, further studies are needed to identify the appropriate candidates for this procedure, establish the optimal PRP preparation method, and standardize the procedure for its adjuvant use in assisted reproductive technology cycles.
ABSTRACT
Background: endometriosis, can cause ovarian conflict and reduced ovarian reserve that could lead to lower response to assisted reproductive techniques
Objective: current study was conducted to determine the association between level of anti-mullerian hormone [AMH] and the infertility treatment outcomes in infertile females with endometriosis versus the non-endometriosis infertile subject
Materials and Methods: in this case-control study, 64 infertile females who referred to Shariati Hospital from April 2015 to November 2017 were enrolled. They were divided in two groups of 32 patients [endometriosis and non-endometriosis women]. The anti-mullerian hormone level among all subjects was determined, treatment outcomes were evaluated and association between these factors was assessed
Results: it was seen that the anti-mullerian hormone [p=0.06], the number of retrieved oocytes [p=0.7] and embryos [p=0.7], implantation rate [p=0.6] and clinical pregnancy rate [p=0.9] were similar between two groups. In patients with stage 3 or 4 endometriosis who had lower serum AMH level significantly [p=0.001] less oocytes were retrieved [p=0.001] and less transferrable embryos [p=0.03] were achieved. However, implantation and pregnancy rates did not differ [p=0.7] [p=0.6]
Conclusion: totally, according to the obtained results, it may be concluded that ovarian reserve has more significant role in predicting infertility treatment outcome rather than receptive endometrium